Analysis · Money

Explained: How CSL makes its money

Add Ticker News on Google
In this story

CSL began as a government laboratory making vaccines for Australians. Today it is a global biotech giant built on donated blood plasma. Here’s how it makes its money, and why it has been through a rough patch.

CSL is Australia’s largest biotechnology company and one of the biggest companies on the ASX.

It started in 1916 as the Commonwealth Serum Laboratories, a government body set up to make vaccines and medicines for Australians. It was privatised and listed on the ASX in 1994, and has since grown into a global business that sells its medicines in more than 100 countries.

CSL reports in U.S. dollars, because most of its sales are overseas. Its financial year ends on 30 June.

Plasma, vaccines and iron

The biggest part of the business is CSL Behring, which brought in about US$11.4 billion of revenue in the 2026 financial year.

It collects plasma, the liquid part of blood, from donors at collection centres, mostly in the U.S. The plasma is then separated into proteins and turned into treatments. Its most important products are immunoglobulins, which help people with weakened immune systems fight infection, along with albumin and treatments for bleeding disorders such as haemophilia.

Plasma medicines are expensive and difficult to make, and collecting plasma takes a large network of centres, so there are only a handful of major producers worldwide.

CSL Seqirus is one of the world’s largest makers of flu vaccines. It also makes vaccines in Melbourne for Australia, including for pandemics. CSL had planned to split it off into a separate company, but delayed that plan in October 2025.

Christian and Democratic Union – Czechoslovak People's Party Office, Karlovo square, Prague.
Christian and Democratic Union – Czechoslovak People's Party Office, Karlovo square, Prague. Photo: Czech Wikipedia user Packa / Wikimedia Commons, CC BY-SA 2.5

CSL Vifor, bought in 2022 for about US$11.7 billion, sells treatments for iron deficiency and kidney disease. Some of its iron products now face cheaper generic competition.

A reset

CSL’s 2026 financial year was a reset. Chief executive Paul McKenzie retired in February 2026, and long-time senior executive Gordon Naylor became interim chief executive. The company wrote down the value of parts of the business, including Vifor, and is cutting costs, closing some underperforming U.S. plasma centres and reducing its workforce.

In October 2026, CSL named Deborah Waterhouse, the head of HIV drug company ViiV Healthcare, as its next chief executive, starting on 1 February 2027.

The risks include the cost of collecting plasma, competition from new drugs that could reduce demand for some plasma treatments, pricing pressure from governments, and changes to health policy in the U.S., its biggest market.

Latest results, as at 9 November 2026

Full year to June 2026, reported 18 August 2026: revenue fell 1 per cent to US$15.8 billion, and underlying profit fell 2 per cent to US$3.1 billion. After US$7.1 billion of write-downs and restructuring costs, CSL posted a statutory loss of US$2.6 billion. It held its dividend steady and announced a $1 billion share buyback.

For the 2027 financial year, CSL expects underlying profit to grow about 5 per cent, with Behring sales growing, while Vifor’s revenue is expected to fall about 25 per cent because of generic competition. Its shares had their best day in more than 20 years after the result.

Next update: CSL reports its half-year results, to December 2026, in February 2027.

More on this story

Up next
‘The economics of tape are compelling’: Quantum CEO on storage trends

Tape storage gains momentum as hyperscalers seek cost-effective solutions amid AI-driven data storage boom, says Quantum CEO

Read the story →

Comments

No comments yet. Start the conversation.

Comments are checked before they appear. Keep it civil, and please don't make claims about people you can't back up.

Ticker Today takes a daily view of the world of news, politics and business.With Ahron YoungWhisky & Suits explores law, property finance and business over fine whisky.With Imran Khan and Chris ChristofiThe Founders Method explores practical lessons and systems for entrepreneursWith Jonathan Byrt and Jesse LeeworthyThe Connector explores property and urban growth across Australia and the UK.With Belinda CoateThe Property Playbook delivers research-led insights for property investors.With Tim Graham and Terry RyderState of Hospitality explores the challenges facing Australia's hospitality.With Jeremy KoadlowBuying Power helps young professionals enter property and build lasting wealth.With Victor and Reshmi KumarThe Airport Economist explores global trade, business and economic outlooks.With Tim HarcourtMedia Movers explores the trends shaping Australia's media and global news.With James ManningBroker Business explores strategies to build, grow and sustain a business.With Rex AfrasiabiMoney Matters explores practical financial strategies to build lasting wealth.With Dr Steven EnticottBeyond Education explores the ideas and technology shaping future learning.With Greg CampitelliTicker Air explores the latest aviation news, travel trends and developments.With Ahron YoungEarly Years Dialogue explores the issues shaping Australia's early learning.With Paul MondoMarkets and Machines explores AI, regulation and trends shaping the markets.With Chris BergSocial Intelligence explores how social media and AI transform our daily lives.With Dr Karen SutherlandThe AI Edge explores how artificial intelligence reshapes the world economy.With Brad Gastwirth

More from Ticker

Watch

More in Money

View all →